Filtered By:
Source: Clinical Lung Cancer
Cancer: Non-Small Cell Lung Cancer

This page shows you your search results in order of date.

Order by Relevance | Date

Total 16 results found since Jan 2013.

Phosphorylation of CAP1 regulates lung cancer proliferation, migration, and invasion
CONCLUSION: These findings indicated that CAP1 phosphorylation can promote lung cancer proliferation, migration, and invasion. Phosphorylation sites of CAP1 might be a novel target for lung cancer treatment.PMID:34636991 | DOI:10.1007/s00432-021-03819-9
Source: Clinical Lung Cancer - October 12, 2021 Category: Cancer & Oncology Authors: Jie Zeng Xuan Li Long Liang Hongxia Duan Shuanshuan Xie Changhui Wang Source Type: research

CIRP promotes the progression of non-small cell lung cancer through activation of Wnt/beta-catenin signaling via CTNNB1
CONCLUSION: Our results support CIRP as a candidate oncogene in NSCLC and a potential target for NSCLC therapy.PMID:34465343 | PMC:PMC8406911 | DOI:10.1186/s13046-021-02080-9
Source: Clinical Lung Cancer - September 1, 2021 Category: Cancer & Oncology Authors: Yi Liao Jianguo Feng Weichao Sun Chao Wu Jingyao Li Tao Jing Yuteng Liang Yonghui Qian Wenlan Liu Haidong Wang Source Type: research

Down-Regulation of HBXIP Inhibits Non-Small Cell Lung Cancer Growth and Enhances the Anti-Tumor Immunity of Mice by Reducing NRP-1
CONCLUSION: Down-regulation of HBXIP reduced Lin28B-mediated NRP-1 to suppress NSCLC cell growth and enhance anti-tumor immunity.PMID:34452886
Source: Clinical Lung Cancer - August 28, 2021 Category: Cancer & Oncology Authors: Lulu Wang Mao Sun Xing Lin Yongyang Lei Zhe Yin Wei Zhou Source Type: research

KRAS inhibitor-resistance in MET-amplified KRAS (G12C) non-small cell lung cancer induced by RAS- and non-RAS-mediated cell signaling mechanisms
CONCLUSIONS: MET amplification leads to the development of resistance to KRAS G12C inhibitors in NSCLC. Dual blockade of MET and KRAS G12C could be a treatment option for MET amplified, KRAS G12C-mutated NSCLC.PMID:34365406 | DOI:10.1158/1078-0432.CCR-21-0856
Source: Clinical Lung Cancer - August 8, 2021 Category: Cancer & Oncology Authors: Shinichiro Suzuki Kimio Yonesaka Takeshi Teramura Toshiyuki Takehara Ryoji Kato Hitomi Sakai Koji Haratani Junko Tanizaki Hisato Kawakami Hidetoshi Hayashi Kazuko Sakai Kazuto Nishio Kazuhiko Nakagawa Source Type: research

Inhibition of yes-associated protein suppresses migration, invasion, and metastasis in non-small cell lung cancer in vitro and in vivo
Clin Exp Med. 2021 Jul 1. doi: 10.1007/s10238-021-00738-4. Online ahead of print.ABSTRACTNon-small cell lung cancer (NSCLC) is a highly aggressive cancer with one of the most prevalent malignant tumors. Metastasis in NSCLC is the major cause of treatment failure and cancer-related deaths. Yes-associated protein (YAP) is a transcriptional coactivator regulated by the evolutionarily conserved Hippo signaling pathway that regulates organ size, growth, and regeneration. YAP is highly expressed in several malignant tumor types. Furthermore, YAP promotes tumor initiation and/or progression in various types of cancer. However, it...
Source: Clinical Lung Cancer - July 1, 2021 Category: Cancer & Oncology Authors: Tomoya Takeda Masanobu Tsubaki Shuji Genno Takuya Matsuda Yuuta Yamamoto Akihiro Kimura Nao Shimizu Shozo Nishida Source Type: research

NUCKS Promotes the Proliferation, Migration and Invasion of Lung Cancer Cells Through Pi3k/Akt Signalling Pathway
CONCLUSION: NUCKS was overexpressed in lung cancer cells and played an important role in lung cancer by increasing cell growth through the PI3K/AKT signalling pathway. This in vitro study suggested NUCKS should be evaluated in a clinical setting as a novel biomarker and potential therapeutic target for lung cancer.PMID:34152708 | DOI:10.25011/cim.v44i2.36246
Source: Clinical Lung Cancer - June 21, 2021 Category: Cancer & Oncology Authors: Cheng Hu Qian Zha Ping Hua Lina Xiao Deng Pan Source Type: research

The arginine methyltransferase PRMT5 and PRMT1 distinctly regulate the degradation of anti-apoptotic protein CFLARL in human lung cancer cells.
CONCLUSIONS: PRMT5 and PRMT1 mediate the distinct effects on CFLARL degradation by regulating the binding of E3 ligase ITCH in NSCLC cells. This study identifies a cell death mechanism that is fine-tuned by PRMT1/5 that modulate CFLARL degradation in human NSCLC cells. PMID: 30736843 [PubMed - in process]
Source: Clinical Lung Cancer - February 8, 2019 Category: Cancer & Oncology Authors: Li M, An W, Xu L, Lin Y, Su L, Liu X Tags: J Exp Clin Cancer Res Source Type: research

Amplification of wild type KRAS imparts resistance to crizotinib in MET exon 14 mutant non-small cell lung cancer.
CONCLUSIONS: Using patient-derived cell line and xenografts, we characterize the mechanism of crizotinib resistance mediated by KRAS amplification in METex14 mutant NSCLC and demonstrate the superior efficacy of the dual MET/PI3K inhibition as a therapeutic strategy addressing this resistance mechanism. PMID: 30072474 [PubMed - as supplied by publisher]
Source: Clinical Lung Cancer - August 2, 2018 Category: Cancer & Oncology Authors: Bahcall M, Awad MM, Sholl LM, Wilson FH, Xu M, Wang S, Palakurthi S, Choi J, Ivanova E, Leonardi GC, Ulrich BC, Paweletz CP, Kirschmeier PT, Watanabe M, Baba H, Nishino M, Nagy RJ, Lanman RB, Capelletti M, Chambers ES, Redig AJ, VanderLaan PA, Costa DB, I Tags: Clin Cancer Res Source Type: research

Role of the NRP-1-mediated VEGFR2-independent pathway on radiation sensitivity of non-small cell lung cancer cells.
CONCLUSIONS: We demonstrated that when VEGFR2 was inhibited, NRP-1 appeared to regulate RAD51 expression through the VEGFR2-independent ABL-1 pathway, consequently regulating radiation sensitivity. In addition, the combined inhibition of VEGFR2 and NRP-1 appears to sensitize cancer cells to radiation. PMID: 29777301 [PubMed - indexed for MEDLINE]
Source: Clinical Lung Cancer - June 30, 2018 Category: Cancer & Oncology Authors: Hu C, Zhu P, Xia Y, Hui K, Wang M, Jiang X Tags: J Cancer Res Clin Oncol Source Type: research

Resveratrol Enhances Etoposide-Induced Cytotoxicity through Down-Regulating ERK1/2 and AKT-Mediated X-ray Repair Cross-Complement Group 1 (XRCC1) Protein Expression in Human Non-Small-Cell Lung Cancer Cells.
This article is protected by copyright. All rights reserved. PMID: 26046675 [PubMed - as supplied by publisher]
Source: Clinical Lung Cancer - June 4, 2015 Category: Cancer & Oncology Authors: Ko JC, Syu JJ, Chen JC, Wang TJ, Chang PY, Chen CY, Jian YT, Jian YJ, Lin YW Tags: Basic Clin Pharmacol Toxicol Source Type: research

miR-107 regulates cisplatin chemosensitivity of A549 non small cell lung cancer cell line by targeting cyclin dependent kinase 8.
In conclusion, the present study provides the first evidence that miR-107 plays a key role in cisplatin resistance by targeting the CDK8 protein in NSCLC cell lines, suggesting that miR-107 can be used to predict a patient's response to chemotherapy as well as serve as a novel potential maker for NSCLC therapy. PMID: 25400821 [PubMed - in process]
Source: Clinical Lung Cancer - November 19, 2014 Category: Cancer & Oncology Authors: Zhang Z, Zhang L, Yin ZY, Fan XL, Hu B, Wang LQ, Zhang D Tags: Int J Clin Exp Pathol Source Type: research

MTA1 promotes the invasion and migration of non-small cell lung cancer cells by downregulating miR-125b.
CONCLUSION: MTA1 and miR-125b have antagonistic effects on the migration and invasion of NSCLC cells. The newly identified MTA1-miR-125b axis will help further elucidate the molecular mechanism of NSCLC progression and suggest that ectopic expression of miR-125b is a potentially new therapeutic regimen against NSCLC metastasis. PMID: 23718732 [PubMed - in process]
Source: Clinical Lung Cancer - June 12, 2013 Category: Cancer & Oncology Authors: Li Y, Chao Y, Fang Y, Wang J, Wang M, Zhang H, Ying M, Zhu X, Wang H Tags: J Exp Clin Cancer Res Source Type: research